von Mässenhausen, A.* ; Schlecht, M.N.* ; Beer, K.* ; Maremonti, F.* ; Tonnus, W.* ; Belavgeni, A.* ; Gavali, S.* ; Flade, K.* ; Riley, J.S.* ; Zamora Gonzalez, N.* ; Brucker, A.J.* ; Becker, J.N.* ; Tmava, M.* ; Meyer, C.* ; Peitzsch, M.* ; Hugo, C.* ; Gembardt, F.* ; Angeli, J.P.F.* ; Bornstein, S.R. ; Tait, S.W.G.* ; Linkermann, A.*
     
 
    
        
Treatment with siRNAs is commonly associated with GPX4 up-regulation and target knockdown-independent sensitization to ferroptosis.
    
    
        
    
    
        
        Sci. Adv. 10:eadk7329 (2024)
    
    
    
		
		
			
				Small interfering RNAs (siRNAs) are widely used in biomedical research and in clinical trials. Here, we demonstrate that siRNA treatment is commonly associated with significant sensitization to ferroptosis, independently of the target protein knockdown. Genetically targeting mitochondrial antiviral-signaling protein (MAVS) reversed the siRNA-mediated sensitizing effect, but no activation of canonical MAVS signaling, which involves phosphorylation of IkBα and interferon regulatory transcription factor 3 (IRF3), was observed. In contrast, MAVS mediated a noncanonical signal resulting in a prominent increase in mitochondrial ROS levels, and increase in the BACH1/pNRF2 transcription factor ratio and GPX4 up-regulation, which was associated with a 50% decrease in intracellular glutathione levels. We conclude that siRNAs commonly sensitize to ferroptosis and may severely compromise the conclusions drawn from silencing approaches in biomedical research. Finally, as ferroptosis contributes to a variety of pathophysiological processes, we cannot exclude side effects in human siRNA-based therapeutical concepts that should be clinically tested.
			
			
				
			
		 
		
			
				
					
					Impact Factor
					Scopus SNIP
					Web of Science
Times Cited
					Scopus
Cited By
					
					Altmetric
					
				 
				
			 
		 
		
     
    
        Publikationstyp
        Artikel: Journalartikel
    
 
    
        Dokumenttyp
        Wissenschaftlicher Artikel
    
 
    
        Typ der Hochschulschrift
        
    
 
    
        Herausgeber
        
    
    
        Schlagwörter
        Clinical-pharmacology; Therapeutics; Necrosis; Pathway; Disease; Death; Risk
    
 
    
        Keywords plus
        
    
 
    
    
        Sprache
        englisch
    
 
    
        Veröffentlichungsjahr
        2024
    
 
    
        Prepublished im Jahr 
        0
    
 
    
        HGF-Berichtsjahr
        2024
    
 
    
    
        ISSN (print) / ISBN
        2375-2548
    
 
    
        e-ISSN
        2375-2548
    
 
    
        ISBN
        
    
 
    
        Bandtitel
        
    
 
    
        Konferenztitel
        
    
 
	
        Konferzenzdatum
        
    
     
	
        Konferenzort
        
    
 
	
        Konferenzband
        
    
 
     
		
    
        Quellenangaben
        
	    Band: 10,  
	    Heft: 11,  
	    Seiten: ,  
	    Artikelnummer: eadk7329 
	    Supplement: ,  
	
    
 
  
        
            Reihe
            
        
 
        
            Verlag
            American Association for the Advancement of Science (AAAS)
        
 
        
            Verlagsort
            Washington, DC [u.a.]
        
 
	
        
            Tag d. mündl. Prüfung
            0000-00-00
        
 
        
            Betreuer
            
        
 
        
            Gutachter
            
        
 
        
            Prüfer
            
        
 
        
            Topic
            
        
 
	
        
            Hochschule
            
        
 
        
            Hochschulort
            
        
 
        
            Fakultät
            
        
 
    
        
            Veröffentlichungsdatum
            0000-00-00
        
 
         
        
            Anmeldedatum
            0000-00-00
        
 
        
            Anmelder/Inhaber
            
        
 
        
            weitere Inhaber
            
        
 
        
            Anmeldeland
            
        
 
        
            Priorität
            
        
 
    
        Begutachtungsstatus
        Peer reviewed
    
 
    
        Institut(e)
        Institute of Pancreatic Islet Research (IPI)
    
 
    
        POF Topic(s)
        90000 - German Center for Diabetes Research
    
 
    
        Forschungsfeld(er)
        Helmholtz Diabetes Center
    
 
    
        PSP-Element(e)
        G-502600-007
    
 
    
        Förderungen
        Cancer Research UK Programme
BMBF (FERROPath consortium)
DFG
International research training group
Heisenberg-Professorship
German Research Foundation
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2024-05-07